Mahyar Etminan1, Brian D Westerberg2, Frederick K Kozak3, Michael Y Guo4, Bruce C Carleton5. 1. Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, Canada. 2. Department of Otolaryngology, University of British Columbia, Vancouver, Canada. 3. Department of Pediatric Otolaryngology, University of British Columbia, Vancouver, Canada. 4. Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, Canada. 5. Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, Canada.
Abstract
OBJECTIVES: To determine the association between a diagnosis of sensorineural hearing loss (SNHL) and the prescription of a macrolide antibiotic. STUDY DESIGN: Retrospective nested case-control study. METHODS: From the LifeLink (IMS, Danbury, CT) health claims database, we randomly selected a cohort of subjects 15 to 60 years old from 2006 to 2014. Cases were identified as patients diagnosed with SNHL, each matched by age and calendar time to 10 controls selected from the same cohort. All macrolide prescriptions (erythromycin, azithromycin, clarithromycin, and telithromycin) were identified, and statistical comparison of usage was compared between cases and controls. Amoxicillin and fluoroquinolone antibiotics were used as positive controls to further investigate confounding by infection. Albuterol was used as a negative control because this is a drug class not expected to be associated with SNHL or with a confounding condition potentially causing SNHL. RESULTS: From a cohort of 6,110,723 subjects, we identified 5,989 cases of SNHL and 59,890 corresponding controls. The rate ratio for one prescription of a macrolide was 1.36 (95% confidence inteval [CI]: 1.24-1.49) and for multiple prescriptions was 1.66 (95% CI: 1.42-1.94). Similar rate ratios were observed with multiple prescriptions of amoxicillin and fluoroquinolones. CONCLUSION: A significant association between SNHL and macrolide use was likely due to confounding by indication for antibiotic treatment because the risk was also observed with fluoroquinolones and amoxicillin, antibiotics with no known ototoxic potential. Therefore, there does not appear to be an increased risk of SNHL in patients treated with macrolide antibiotics. LEVEL OF EVIDENCE: 3b. Laryngoscope, 127:229-232, 2017.
OBJECTIVES: To determine the association between a diagnosis of sensorineural hearing loss (SNHL) and the prescription of a macrolide antibiotic. STUDY DESIGN: Retrospective nested case-control study. METHODS: From the LifeLink (IMS, Danbury, CT) health claims database, we randomly selected a cohort of subjects 15 to 60 years old from 2006 to 2014. Cases were identified as patients diagnosed with SNHL, each matched by age and calendar time to 10 controls selected from the same cohort. All macrolide prescriptions (erythromycin, azithromycin, clarithromycin, and telithromycin) were identified, and statistical comparison of usage was compared between cases and controls. Amoxicillin and fluoroquinolone antibiotics were used as positive controls to further investigate confounding by infection. Albuterol was used as a negative control because this is a drug class not expected to be associated with SNHL or with a confounding condition potentially causing SNHL. RESULTS: From a cohort of 6,110,723 subjects, we identified 5,989 cases of SNHL and 59,890 corresponding controls. The rate ratio for one prescription of a macrolide was 1.36 (95% confidence inteval [CI]: 1.24-1.49) and for multiple prescriptions was 1.66 (95% CI: 1.42-1.94). Similar rate ratios were observed with multiple prescriptions of amoxicillin and fluoroquinolones. CONCLUSION: A significant association between SNHL and macrolide use was likely due to confounding by indication for antibiotic treatment because the risk was also observed with fluoroquinolones and amoxicillin, antibiotics with no known ototoxic potential. Therefore, there does not appear to be an increased risk of SNHL in patients treated with macrolide antibiotics. LEVEL OF EVIDENCE: 3b. Laryngoscope, 127:229-232, 2017.
Authors: Matt Mason; Eric Gregory; Keith Foster; Megan Klatt; Sara Zoubek; Albert J Eid Journal: Open Forum Infect Dis Date: 2022-06-15 Impact factor: 4.423
Authors: Doreen Nakku; Victoria Nyaiteera; Evelyn Llowet; Dennis Nanseera; Gladys Nakalema; Brian Westerberg; Francis Bajunirwe Journal: Int J Pediatr Otorhinolaryngol Date: 2017-08-14 Impact factor: 1.675
Authors: Filippo Ricciardiello; Davide Pisani; Pasquale Viola; Elisabetta Cristiano; Alfonso Scarpa; Antonio Giannone; Giuseppe Longo; Giuseppe Russo; Marco Bocchetti; Ciro Coppola; Marco Perrella; Flavia Oliva; Giuseppe Chiarella Journal: Audiol Res Date: 2021-07-01
Authors: Anna Vanoverschelde; Berthe C Oosterloo; Nelly F Ly; M Arfan Ikram; André Goedegebure; Bruno H Stricker; Lies Lahousse Journal: J Antimicrob Chemother Date: 2021-09-15 Impact factor: 5.790